Skip to main content
Top
Published in: Journal of Ovarian Research 1/2017

Open Access 01-12-2017 | Research

Age is associated with prognosis in serous ovarian carcinoma

Authors: Fei Deng, Xia Xu, Mengmeng Lv, Binhui Ren, Yan Wang, Wenwen Guo, Jifeng Feng, Xiaoxiang Chen

Published in: Journal of Ovarian Research | Issue 1/2017

Login to get access

Abstract

Purpose

The survival duration of elderly patients with epithelial ovarian carcinoma is shorter than that of their younger counterparts. This variation in survival duration is likely attributed to differences in the distribution of histological type or grade, International Federation of Gynecology and Obstetrics (FIGO) staging, and undertreatment, but this observation remains controversial. This study aimed to investigate the biological factors other than selection bias associated with the decreased survival of elderly patients with ovarian carcinoma.

Methods

A total of 314 serous ovarian cancer (SOC) patients from Jiangsu Institute of Cancer Research (JICR, PRC) between 2002 and 2012 were retrospectively analyzed, and 774 cases from MD Anderson Cancer Center (MDACC, USA) between 1992 and 2012 were used for validation. The 8-hydroxy-2′-deoxyguanine (8-OHdG) concentration in leukocyte DNA was evaluated by using commercially available enzyme-linked immunosorbent assay kits, and tissue expression was assayed through immunohistochemistry. The associations between survival durations and covariates were assessed by using a Cox proportional hazards model and by conducting a log-rank test.

Results

Advanced age ≥ 65 years was correlated with high histological grade (p = 0.02), performance status (p = 0.03), primary treatment (p = 0.00), and suboptimal surgery outcome (p = 0.04) in SOC patients from JICR. Age, FIGO stage, histological grade, and optimal surgery were independently associated with the progression-free survival (PFS; p = 0.03, p = 0.03, p = 0.02, and p = 0.04, respectively) and overall survival (OS; p = 0.02, p = 0.04, p = 0.02, and p = 0.02, respectively) of the SOC patients from JICR. The 8-OHdG concentration in the leukocyte DNA was higher in the elderly patients than in the younger cases. The high 8-OHdG concentration in the leukocyte DNA indicated poorer median OS (30.0 months, confidence interval [CI]: 23.5–36.5 vs. 42.8 months, [CI] 38.3–47.2) and PFS (14.6 months, [CI] 11.9–17.2 vs. 18.9 months, [CI] 14.4–23.4) than those of their corresponding counterparts in the SOC patients who achieved a clinical complete response from primary treatment.

Conclusions

Compared with younger cases, elderly patients with SOC were commonly characterized by high tumor grade, poor performance status, and undertreatment. High 8-OHdG concentration in leukocyte DNA was associated with advanced age and poor prognosis in SOC patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Miller KD, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.CrossRefPubMed Miller KD, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.CrossRefPubMed
2.
go back to reference Hannibal CG, et al. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002. Acta Obstet Gynecol Scand. 2008;87(12):1353–60.CrossRefPubMed Hannibal CG, et al. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002. Acta Obstet Gynecol Scand. 2008;87(12):1353–60.CrossRefPubMed
3.
go back to reference Yang L, et al. Statistics on cancer in China: cancer registration in 2002. Eur J Cancer Prev. 2005;14(4):329–35.CrossRefPubMed Yang L, et al. Statistics on cancer in China: cancer registration in 2002. Eur J Cancer Prev. 2005;14(4):329–35.CrossRefPubMed
4.
go back to reference Howlader, N., et al., SEER cancer statistics review, 1975–2010, National Cancer Institute. Bethesda, MD, based on November 2012 SEER data submission, posted to the SEER web site, 2013. 2013. Howlader, N., et al., SEER cancer statistics review, 1975–2010, National Cancer Institute. Bethesda, MD, based on November 2012 SEER data submission, posted to the SEER web site, 2013. 2013.
6.
go back to reference Zhou J, et al. Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study. Oncotarget. 2016;7(7):7952–9.PubMedPubMedCentral Zhou J, et al. Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study. Oncotarget. 2016;7(7):7952–9.PubMedPubMedCentral
7.
go back to reference Rauh-Hain JA, et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol. 2013;131(1):46–51.CrossRefPubMed Rauh-Hain JA, et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol. 2013;131(1):46–51.CrossRefPubMed
8.
go back to reference Terplan M, et al. Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol. 2012;125(1):19–24.CrossRefPubMed Terplan M, et al. Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol. 2012;125(1):19–24.CrossRefPubMed
9.
go back to reference Rouzier R, et al. The role of lymph node resection in ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database. BJOG. 2010;117(12):1451–8.CrossRefPubMed Rouzier R, et al. The role of lymph node resection in ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database. BJOG. 2010;117(12):1451–8.CrossRefPubMed
10.
go back to reference Gibson SJ, et al. The application and outcome of standard of care treatment in elderly women with ovarian cancer: a literature review over the last 10 years. Front Oncol. 2016;6:63.CrossRefPubMedPubMedCentral Gibson SJ, et al. The application and outcome of standard of care treatment in elderly women with ovarian cancer: a literature review over the last 10 years. Front Oncol. 2016;6:63.CrossRefPubMedPubMedCentral
11.
go back to reference Langstraat C, Cliby WA. Considerations in the surgical management of ovarian cancer in the elderly. Curr Treat Options in Oncol. 2013;14(1):12–21.CrossRef Langstraat C, Cliby WA. Considerations in the surgical management of ovarian cancer in the elderly. Curr Treat Options in Oncol. 2013;14(1):12–21.CrossRef
12.
go back to reference Malvezzi M, et al. Global trends and predictions in ovarian cancer mortality. Ann Oncol. 2016;27(11):2017–25.CrossRefPubMed Malvezzi M, et al. Global trends and predictions in ovarian cancer mortality. Ann Oncol. 2016;27(11):2017–25.CrossRefPubMed
13.
go back to reference Sabatier R, et al. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study. Int J Gynecol Cancer. 2015;25(5):815–22.CrossRefPubMed Sabatier R, et al. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study. Int J Gynecol Cancer. 2015;25(5):815–22.CrossRefPubMed
14.
go back to reference Uyar D, et al. Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol. 2005;98(3):403–8.CrossRefPubMed Uyar D, et al. Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol. 2005;98(3):403–8.CrossRefPubMed
15.
go back to reference Aletti GD, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011;120(1):23–8.CrossRefPubMed Aletti GD, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011;120(1):23–8.CrossRefPubMed
16.
17.
go back to reference Chen X, et al. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol. 2013;44(11):2373–84.CrossRefPubMedPubMedCentral Chen X, et al. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol. 2013;44(11):2373–84.CrossRefPubMedPubMedCentral
18.
20.
go back to reference Wang F, et al. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res. 2013;6(1):14.CrossRefPubMedPubMedCentral Wang F, et al. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res. 2013;6(1):14.CrossRefPubMedPubMedCentral
21.
go back to reference Corvino R, et al. Long-lasting stent placement in an elderly advanced ovarian cancer patient. Oncol Res Treat. 2016;39(3):146–8.CrossRefPubMed Corvino R, et al. Long-lasting stent placement in an elderly advanced ovarian cancer patient. Oncol Res Treat. 2016;39(3):146–8.CrossRefPubMed
23.
go back to reference Barber EL, et al. A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery. Gynecol Oncol. 2015;139(3):401–6.CrossRefPubMedPubMedCentral Barber EL, et al. A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery. Gynecol Oncol. 2015;139(3):401–6.CrossRefPubMedPubMedCentral
24.
go back to reference Joseph N, et al. Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Gynecol Oncol. 2015;137(3):401–5.CrossRefPubMed Joseph N, et al. Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Gynecol Oncol. 2015;137(3):401–5.CrossRefPubMed
25.
go back to reference Bun S, et al. Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2016;78(4):745–52.CrossRefPubMed Bun S, et al. Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2016;78(4):745–52.CrossRefPubMed
26.
go back to reference Turrentine FE, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203(6):865–77.CrossRefPubMed Turrentine FE, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203(6):865–77.CrossRefPubMed
27.
go back to reference Gerestein CG, et al. Causes of postoperative mortality after surgery for ovarian cancer. Eur J Cancer. 2009;45(16):2799–803.CrossRefPubMed Gerestein CG, et al. Causes of postoperative mortality after surgery for ovarian cancer. Eur J Cancer. 2009;45(16):2799–803.CrossRefPubMed
28.
go back to reference Barber EL, et al. Corrigendum to 'A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery' Gynecol. Oncol. 139 (2015) start 401-406. Gynecol Oncol. 2016;142(2):380.CrossRefPubMed Barber EL, et al. Corrigendum to 'A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery' Gynecol. Oncol. 139 (2015) start 401-406. Gynecol Oncol. 2016;142(2):380.CrossRefPubMed
30.
go back to reference Sharma S, et al. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol. 2005;193(6):2077–82.CrossRefPubMed Sharma S, et al. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol. 2005;193(6):2077–82.CrossRefPubMed
31.
go back to reference Susini T, et al. Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients. Int J Gynecol Cancer. 2007;17(3):581–8.CrossRefPubMed Susini T, et al. Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients. Int J Gynecol Cancer. 2007;17(3):581–8.CrossRefPubMed
32.
go back to reference Janda M, et al. Elderly patients with stage III or IV ovarian cancer: should they receive standard care? Int J Gynecol Cancer. 2008;18(5):896–907.CrossRefPubMed Janda M, et al. Elderly patients with stage III or IV ovarian cancer: should they receive standard care? Int J Gynecol Cancer. 2008;18(5):896–907.CrossRefPubMed
33.
go back to reference Balducci L, et al. Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2005;3(4):572–90.CrossRef Balducci L, et al. Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2005;3(4):572–90.CrossRef
34.
go back to reference Balducci L. Management of cancer in the elderly. Oncology (Williston Park). 2006;20(2):135–43. discussion 144, 146, 151-2 Balducci L. Management of cancer in the elderly. Oncology (Williston Park). 2006;20(2):135–43. discussion 144, 146, 151-2
35.
go back to reference Pignata S, Vermorken JB. Ovarian cancer in the elderly. Crit Rev Oncol Hematol. 2004;49(1):77–86.CrossRefPubMed Pignata S, Vermorken JB. Ovarian cancer in the elderly. Crit Rev Oncol Hematol. 2004;49(1):77–86.CrossRefPubMed
36.
go back to reference Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.CrossRef Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.CrossRef
37.
go back to reference Cai Z, et al. Association of base excision repair gene polymorphisms with ESRD risk in a Chinese population. Oxidative Med Cell Longev. 2012;2012:928421.CrossRef Cai Z, et al. Association of base excision repair gene polymorphisms with ESRD risk in a Chinese population. Oxidative Med Cell Longev. 2012;2012:928421.CrossRef
38.
go back to reference Sun C, et al. A common mutation of the MYH gene is associated with increased DNA oxidation and age-related diseases. Free Radic Biol Med. 2010;48(3):430–6.CrossRefPubMed Sun C, et al. A common mutation of the MYH gene is associated with increased DNA oxidation and age-related diseases. Free Radic Biol Med. 2010;48(3):430–6.CrossRefPubMed
39.
go back to reference Sun C, et al. Functional polymorphism of hOGG1 gene is associated with type 2 diabetes mellitus in Chinese population. Mol Cell Endocrinol. 2010;325(1–2):128–34.CrossRefPubMed Sun C, et al. Functional polymorphism of hOGG1 gene is associated with type 2 diabetes mellitus in Chinese population. Mol Cell Endocrinol. 2010;325(1–2):128–34.CrossRefPubMed
40.
go back to reference Shanmughapriya S, et al. Risk factors for epithelial ovarian carcinoma in India: a case control study in low-incidence population. International Journal of Cancer Research. 2016;12(1):1–8.CrossRef Shanmughapriya S, et al. Risk factors for epithelial ovarian carcinoma in India: a case control study in low-incidence population. International Journal of Cancer Research. 2016;12(1):1–8.CrossRef
41.
go back to reference Yoshikawa N, et al. Clinicopathologic features of epithelial ovarian carcinoma in younger vs. older patients: analysis in Japanese women. J Gynecol Oncol. 2014;25(2):118–23.CrossRefPubMedPubMedCentral Yoshikawa N, et al. Clinicopathologic features of epithelial ovarian carcinoma in younger vs. older patients: analysis in Japanese women. J Gynecol Oncol. 2014;25(2):118–23.CrossRefPubMedPubMedCentral
42.
go back to reference Bozas G, et al. Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology. 2006;70(70):265–72.CrossRefPubMed Bozas G, et al. Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology. 2006;70(70):265–72.CrossRefPubMed
43.
go back to reference Thigpen T, et al. Age as a prognostic factor in ovarian carcinoma: the gynecologic oncology group experience. Cancer. 1993;71(Supplement):606–14.PubMed Thigpen T, et al. Age as a prognostic factor in ovarian carcinoma: the gynecologic oncology group experience. Cancer. 1993;71(Supplement):606–14.PubMed
44.
go back to reference Woopen H, et al. Elderly ovarian cancer patients: an individual participant data meta-analysis of the north-eastern German Society of Gynecological Oncology (NOGGO). Eur J Cancer. 2016;60:101–6.CrossRefPubMed Woopen H, et al. Elderly ovarian cancer patients: an individual participant data meta-analysis of the north-eastern German Society of Gynecological Oncology (NOGGO). Eur J Cancer. 2016;60:101–6.CrossRefPubMed
45.
go back to reference Chia VM, et al. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol. 2013;129(2):346–52.CrossRefPubMed Chia VM, et al. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol. 2013;129(2):346–52.CrossRefPubMed
46.
go back to reference Mooney SJ, et al. Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol Oncol. 2013;129(1):107–12.CrossRefPubMed Mooney SJ, et al. Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol Oncol. 2013;129(1):107–12.CrossRefPubMed
47.
go back to reference Trillsch F, et al. Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. J Ovarian Res. 2013;6(1):42.CrossRefPubMedPubMedCentral Trillsch F, et al. Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. J Ovarian Res. 2013;6(1):42.CrossRefPubMedPubMedCentral
48.
go back to reference Tew WP. Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer. Curr Treat Options in Oncol. 2013;14(1):1–11.CrossRef Tew WP. Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer. Curr Treat Options in Oncol. 2013;14(1):1–11.CrossRef
49.
go back to reference Muralikrishnan S, et al. Chemotherapy for elderly ovarian cancer patients. Gynecol Obstet (Sunnyvale). 2016:6(8). Muralikrishnan S, et al. Chemotherapy for elderly ovarian cancer patients. Gynecol Obstet (Sunnyvale). 2016:6(8).
50.
go back to reference Poonawalla IB, et al. Impact of hematopoietic growth factors on blood transfusion needs, incidence of Neutropenia, and overall survival among elderly advanced ovarian cancer patients treated with chemotherapy. Int J Gynecol Cancer. 2016;26(1):95–103.CrossRefPubMed Poonawalla IB, et al. Impact of hematopoietic growth factors on blood transfusion needs, incidence of Neutropenia, and overall survival among elderly advanced ovarian cancer patients treated with chemotherapy. Int J Gynecol Cancer. 2016;26(1):95–103.CrossRefPubMed
51.
go back to reference Tinquaut F, et al. Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: results of a pooled analysis of three GINECO phase II trials. Gynecol Oncol. 2016;143(1):22–6.CrossRefPubMed Tinquaut F, et al. Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: results of a pooled analysis of three GINECO phase II trials. Gynecol Oncol. 2016;143(1):22–6.CrossRefPubMed
52.
53.
go back to reference Falandry C, et al. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol. 2013;24(11):2808–13.CrossRefPubMed Falandry C, et al. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol. 2013;24(11):2808–13.CrossRefPubMed
54.
go back to reference Troso-Sandoval TA, Lichtman SM. Chemotherapy of ovarian cancer in elderly patients. Cancer Biol Med. 2015;12(4):292–301.PubMedPubMedCentral Troso-Sandoval TA, Lichtman SM. Chemotherapy of ovarian cancer in elderly patients. Cancer Biol Med. 2015;12(4):292–301.PubMedPubMedCentral
Metadata
Title
Age is associated with prognosis in serous ovarian carcinoma
Authors
Fei Deng
Xia Xu
Mengmeng Lv
Binhui Ren
Yan Wang
Wenwen Guo
Jifeng Feng
Xiaoxiang Chen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2017
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-017-0331-6

Other articles of this Issue 1/2017

Journal of Ovarian Research 1/2017 Go to the issue